Leading pharma companies are achieving rapid, large-scale performance improvements using a multifaceted approach that realizes short-term gains & builds long-term capabilities at the same time
With the approval from the Central Drugs Standard Control Organisation (CDSCO), Jardiance is now the first approved therapy to improve outcomes for the full spectrum of heart failure regardless of ejection fraction
It is part of the company's CAD $30 million capital investment in the Aurora, Canada site
City of Hope is first in world to test oncolytic virus, CF33-hNIS, in people with metastatic solid tumours
ZS and Quartic will collaborate to help drive resilience, increase adoption of Industry 4.0 and improve predictive decision-making across manufacturing
Viralex (Inosine Pranobex) is an immunomodulatory agent with broad-spectrum antiviral properties
Wearable patch sensors (smart patches) are rising in popularity, as they offer a wide range of options for medical diagnosis
Multiples is the first private equity (PE) investor in the company
Moderna continues to expand its mRNA platform for a range of additional clinical applications and routes of administration including a modality for lung delivery
The study will evaluate the effectiveness of Nantheia ATL5, an investigational drug using cannabidiol in ANANDA’s proprietary delivery technology
Subscribe To Our Newsletter & Stay Updated
